Caldera Medical Launches Women’s Health Initiative

Company announces humanitarian initiative toward alleviating one million women suffering from Incontinence and Prolapse by 2025

AGOURA HILLS, Calif.--(BUSINESS WIRE)--Caldera Medical, a medical device company that develops differentiated surgical implants for the treatment of Stress Urinary Incontinence (SUI) and Pelvic Organ Prolapse (POP), has launched Women’s Health Initiative, to treat women suffering from SUI and POP. Women’s Health Initiative partners with leading surgeons to advance education and provide humanitarian aid while delivering care to impoverished women suffering from SUI and POP regardless of their ability to pay. The initiative specifically involves dispatching teams of surgeons to underprivileged areas to treat patients and provide proper training to local physicians.

“Millions of women in poverty-stricken countries are incapacitated by incontinence and/or prolapse and are not being treated”

Urinary Incontinence, also known as the “silent epidemic,” is a common condition that affects millions of women during adult life. Recent statistics show that 348 million people worldwide experienced some type of incontinence in 2008, and this number is projected to increase to 423 million by 2018. In 2008 a total of 250 million women in Asia, South America and Africa were affected by incontinence and this number is expected to increase to approximately 303 million by 2018. SUI has a severe impact on quality of life, affecting psychological health, social function, body image and overall well-being. Although SUI is a common problem among women and can seriously affect their quality of life, most women do not seek or have access to medical help.

It is estimated that Pelvic Organ Prolapse affects 34 million women worldwide, yet so many of these women are often too embarrassed to discuss this problem with their own doctor. As a result, many of these women suffer from this untreated condition for decades. Oftentimes women may suffer from urinary incontinence and pelvic organ prolapse concurrently and still not seek help.

“Millions of women in poverty-stricken countries are incapacitated by incontinence and/or prolapse and are not being treated,” stated Caldera Medical’s CEO Bryon L. Merade, adding, “We are committed in heart and mind to alleviate one million women suffering from Incontinence and Prolapse by 2025!”

About Caldera Medical

Caldera Medical is dedicated to improving the quality of life for women. Caldera Medical develops and markets differentiated surgical implants across the gynecological, urological and urogynecological specialties.

Caldera Medical’s product lines include the Desara^® Sling System for treatment of SUI and Vertessa^® Lite, lightweight, flexible yet strong polypropylene mesh for use in abdominal sacrocolpopexy procedures for the treatment of POP.

Caldera Medical is a privately held company located in Agoura Hills, California. For more information, visit Caldera Medical's Web site at www.CalderaWHI.com or www.Calderamedical.com.